vs

Side-by-side financial comparison of AMES NATIONAL CORP (ATLO) and Zymeworks Inc. (ZYME). Click either name above to swap in a different company.

Zymeworks Inc. is the larger business by last-quarter revenue ($27.6M vs $18.7M, roughly 1.5× AMES NATIONAL CORP). AMES NATIONAL CORP runs the higher net margin — 34.9% vs -71.0%, a 105.9% gap on every dollar of revenue. On growth, Zymeworks Inc. posted the faster year-over-year revenue change (72.6% vs 26.7%). AMES NATIONAL CORP produced more free cash flow last quarter ($20.7M vs $-31.8M).

Ames National Corp is a U.S. financial holding company based in Iowa. It operates multiple community banking subsidiaries, offering retail and commercial financial services including deposit accounts, personal and business loans, mortgages, and wealth management, primarily serving consumers and SMEs across central Iowa.

Zymeworks Inc. is a publicly held biotechnology company based in Vancouver, British Columbia, that develops protein therapeutics for the treatment of cancer as well as for autoimmune and inflammatory diseases. The products are based upon the company's molecular modeling software for optimizing protein structure. In 2014, Zymeworks raised $44 million across various funding rounds according to PitchBook, placing it among the top 10 HealthTech businesses in the world to raise the most capital th...

ATLO vs ZYME — Head-to-Head

Bigger by revenue
ZYME
ZYME
1.5× larger
ZYME
$27.6M
$18.7M
ATLO
Growing faster (revenue YoY)
ZYME
ZYME
+45.9% gap
ZYME
72.6%
26.7%
ATLO
Higher net margin
ATLO
ATLO
105.9% more per $
ATLO
34.9%
-71.0%
ZYME
More free cash flow
ATLO
ATLO
$52.5M more FCF
ATLO
$20.7M
$-31.8M
ZYME

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
ATLO
ATLO
ZYME
ZYME
Revenue
$18.7M
$27.6M
Net Profit
$6.5M
$-19.6M
Gross Margin
Operating Margin
44.3%
-80.1%
Net Margin
34.9%
-71.0%
Revenue YoY
26.7%
72.6%
Net Profit YoY
85.4%
34.3%
EPS (diluted)
$-0.26

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ATLO
ATLO
ZYME
ZYME
Q4 25
$18.7M
Q3 25
$16.6M
$27.6M
Q2 25
$16.1M
$48.7M
Q1 25
$15.5M
$27.1M
Q4 24
$14.7M
$31.0M
Q3 24
$13.5M
$16.0M
Q2 24
$13.5M
$19.2M
Q1 24
$13.1M
$10.0M
Net Profit
ATLO
ATLO
ZYME
ZYME
Q4 25
$6.5M
Q3 25
$4.6M
$-19.6M
Q2 25
$4.5M
$2.3M
Q1 25
$3.4M
$-22.6M
Q4 24
$3.5M
$-23.5M
Q3 24
$2.2M
$-29.9M
Q2 24
$2.2M
$-37.7M
Q1 24
$2.3M
$-31.7M
Operating Margin
ATLO
ATLO
ZYME
ZYME
Q4 25
44.3%
Q3 25
34.5%
-80.1%
Q2 25
35.0%
-1.4%
Q1 25
27.4%
-94.5%
Q4 24
29.4%
-71.6%
Q3 24
19.4%
-213.8%
Q2 24
19.0%
-222.9%
Q1 24
20.8%
-376.9%
Net Margin
ATLO
ATLO
ZYME
ZYME
Q4 25
34.9%
Q3 25
27.5%
-71.0%
Q2 25
28.0%
4.8%
Q1 25
22.3%
-83.5%
Q4 24
23.8%
-75.8%
Q3 24
16.4%
-186.6%
Q2 24
16.2%
-195.8%
Q1 24
17.6%
-315.6%
EPS (diluted)
ATLO
ATLO
ZYME
ZYME
Q4 25
Q3 25
$-0.26
Q2 25
$0.03
Q1 25
$-0.30
Q4 24
$-0.32
Q3 24
$-0.39
Q2 24
$-0.49
Q1 24
$-0.42

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ATLO
ATLO
ZYME
ZYME
Cash + ST InvestmentsLiquidity on hand
$126.8M
$64.8M
Total DebtLower is stronger
$18.4M
Stockholders' EquityBook value
$207.9M
$320.1M
Total Assets
$2.1B
$397.3M
Debt / EquityLower = less leverage
0.09×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ATLO
ATLO
ZYME
ZYME
Q4 25
$126.8M
Q3 25
$108.2M
$64.8M
Q2 25
$95.2M
$98.3M
Q1 25
$163.4M
$76.2M
Q4 24
$101.2M
$66.1M
Q3 24
$59.0M
$122.4M
Q2 24
$63.4M
$71.0M
Q1 24
$111.4M
$114.8M
Total Debt
ATLO
ATLO
ZYME
ZYME
Q4 25
$18.4M
Q3 25
Q2 25
Q1 25
Q4 24
$20.0M
Q3 24
Q2 24
Q1 24
Stockholders' Equity
ATLO
ATLO
ZYME
ZYME
Q4 25
$207.9M
Q3 25
$200.6M
$320.1M
Q2 25
$193.0M
$334.5M
Q1 25
$183.1M
$325.0M
Q4 24
$174.7M
$338.8M
Q3 24
$183.4M
$367.0M
Q2 24
$167.1M
$406.2M
Q1 24
$165.5M
$438.0M
Total Assets
ATLO
ATLO
ZYME
ZYME
Q4 25
$2.1B
Q3 25
$2.1B
$397.3M
Q2 25
$2.1B
$408.4M
Q1 25
$2.2B
$425.5M
Q4 24
$2.1B
$463.1M
Q3 24
$2.1B
$487.2M
Q2 24
$2.1B
$515.6M
Q1 24
$2.2B
$553.8M
Debt / Equity
ATLO
ATLO
ZYME
ZYME
Q4 25
0.09×
Q3 25
Q2 25
Q1 25
Q4 24
0.11×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ATLO
ATLO
ZYME
ZYME
Operating Cash FlowLast quarter
$21.3M
$-31.4M
Free Cash FlowOCF − Capex
$20.7M
$-31.8M
FCF MarginFCF / Revenue
110.8%
-115.2%
Capex IntensityCapex / Revenue
3.4%
1.5%
Cash ConversionOCF / Net Profit
3.28×
TTM Free Cash FlowTrailing 4 quarters
$34.2M
$-65.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ATLO
ATLO
ZYME
ZYME
Q4 25
$21.3M
Q3 25
$2.8M
$-31.4M
Q2 25
$4.0M
$12.1M
Q1 25
$7.1M
$-3.4M
Q4 24
$14.3M
$-41.5M
Q3 24
$3.1M
$-5.9M
Q2 24
$3.9M
$-25.0M
Q1 24
$1.4M
$-37.7M
Free Cash Flow
ATLO
ATLO
ZYME
ZYME
Q4 25
$20.7M
Q3 25
$2.6M
$-31.8M
Q2 25
$3.9M
$11.6M
Q1 25
$6.9M
$-3.4M
Q4 24
$14.0M
$-41.8M
Q3 24
$3.0M
$-6.8M
Q2 24
$3.8M
$-25.6M
Q1 24
$1.3M
$-37.9M
FCF Margin
ATLO
ATLO
ZYME
ZYME
Q4 25
110.8%
Q3 25
16.0%
-115.2%
Q2 25
24.2%
23.7%
Q1 25
44.8%
-12.6%
Q4 24
94.9%
-134.8%
Q3 24
22.5%
-42.4%
Q2 24
28.1%
-133.0%
Q1 24
10.0%
-377.5%
Capex Intensity
ATLO
ATLO
ZYME
ZYME
Q4 25
3.4%
Q3 25
0.6%
1.5%
Q2 25
0.7%
1.1%
Q1 25
1.3%
0.1%
Q4 24
2.0%
1.0%
Q3 24
0.5%
5.6%
Q2 24
0.7%
3.1%
Q1 24
0.5%
1.8%
Cash Conversion
ATLO
ATLO
ZYME
ZYME
Q4 25
3.28×
Q3 25
0.60×
Q2 25
0.89×
5.21×
Q1 25
2.07×
Q4 24
4.07×
Q3 24
1.40×
Q2 24
1.78×
Q1 24
0.59×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons